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Abstract: Despite the fact that the retina is a fairly accessible portion of the central nervous 
system, there are virtually no treatments for early age-related macular degeneration (AMD). 
AMD is a degenerative retinal disease that causes progressive loss of central vision and is the 
leading cause of irreversible vision loss and legal blindness in individuals over the age of 50. Both 
environmental and genetic components play a role in its development. AMD is a multifactorial 
disease with characteristics that include drusen, hyperpigmentation and/or hypopigmentation 
of the retinal pigment epithelium (RPE), geographic atrophy and, in a subset of patients, late-
stage choroidal neovascularization (CNV). Drugs that inhibit vascular endothelial growth 
factor (VEGF) have proven effective in treating late-stage CNV, but optimal means of drug 
delivery remains to be determined. Microscopic particles, whose size is on the nanometer scale, 
show considerable promise for drug delivery to the retina, for gene therapy, and for powering 
prosthetic “artiﬁ  cial retinas.” This article summarizes the pathophysiology of AMD stressing 
potential applications from nanotechnology.
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Introduction
Age-related macular degeneration (AMD) is a degenerative retinal disease that 
causes progressive loss of central vision. AMD is the leading cause of irreversible 
vision loss and legal blindness in individuals over the age of 50; according to the 
National Eye Institute (NEI), it is most common in people in their 70s. The risk of 
developing macular degeneration increases with age. The acronyms ARMD, ARM, 
and AMD are often used interchangeably. Early disease is sometimes referred to as 
age-related maculopathy “ARM” and late disease (geographic atrophy or choroidal 
neovascularization) “AMD,” but use of this terminology is not universal. Here, for 
simplicity, we will use “AMD” to refer to the spectrum of disease. Although some 
treatments to slow progression are available for AMD, there is currently no cure for this 
irreversible disease. Recently, nanotechnology has emerged as an approach with great 
potential for unique medical applications. Nanotechnology involves using nanoparticles 
(NPs) which are microscopic particles whose size is on the nanometer scale. These 
NPs can be synthesized with organic, inorganic polymers or a combination of both 
polymers in various molecular sizes and conformations allowing for encapsulation of 
speciﬁ  cally adapted formulations. Also, they can be made biodegradable. It is these 
properties of NPs that have encouraged research into their possible application in the 
prevention of ARM and the treatment of AMD.
The available data on the prevalence of AMD are estimates obtained by extrapolation 
from independent studies involving a few thousand individuals. The non-uniform 
classiﬁ  cation of AMD in these studies makes it even more difﬁ  cult to make accurate 
estimates. According to the NEI and Prevent Blindness America’s (PBA’s) Vision Problems 
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in the US report, 1.65 million Americans age 50 and older 
have advanced stages of AMD, and this number is expected 
to double by 2020 (Friedman et al 2004). Worldwide, as many 
as 30 million people have AMD of various stages. About 11 
million Americans are potentially at risk for AMD. It is estimated 
that about 15–17 million people in the US may have symptoms of 
AMD and that 2 million have functional blindness; 200 000–500 
000 new cases are diagnosed each year (Massof 2002). Some 
studies suggest more women than men will get macular 
degeneration, but this may be a consequence of a greater 
longevity for women. As many 20% of people over age 60 
develop AMD and the risk jumps dramatically to as many 
as 40% over age 75 (VanNewkirk et al 2000). Recently, in a 
large study with three racially similar populations of 14 752 
participants from North America, Europe, and Australia, the 
prevalence of AMD was found to be 0.2% of the combined 
population aged 55–64 years, rising to 13% of the population 
older than 85 years. There is also a striking racial difference. 
AMD is very uncommon in native African people and 
Aboriginal Australians. It is uncommon in the US in African 
Americans, slightly more common in Hispanic Americans, 
and quite common in European Americans.
Etiology, risk factors, and prevention 
AMD is a multi-factorial disease; both environmental and 
genetic components play a role in its development. The 
exact causes and the underlying pathomechanisms are not 
known but several risk factors have been linked to AMD. 
These include age, gender, social class, race, ethnicity, family 
history of AMD, smoking, cardiovascular disease, high blood 
pressure, dietary fat intake, cholesterol levels, alcohol 
consumption, estrogen levels, light exposure (UV-A and UV-
B rays), and low dietary intake of antioxidants (Evans 2002). 
Current evidence suggests that progression may be slowed 
with a diet rich in leafy green vegetables, antioxidants, zinc, 
avoidance of excessive sunlight, and smoking. As for the 
family history, it has been shown that siblings of a person 
with AMD have four times greater chance of developing the 
disease than those who had no relatives with AMD. In the 
case of identical twins, there is a 40%–100% chance that 
the other twin develops AMD. For non-identical twins there 
is a 20%–40% probability (Hammond et al 2002).
Types, classiﬁ  cation, signs, 
and symptoms
AMD is classified into two types: “dry” (atrophic or 
nonexudative) and “wet” (neovascular or exudative) forms. 
The “dry” form is the most common form (90%) and usually 
progresses slowly. The “wet” form is rare (10%), more 
severe, and may progress rapidly and cause the most severe 
vision loss. The characteristic lesions of dry AMD are soft 
drusen (63 micron or larger) and changes in pigmentation 
(hypo-, and/or hyperpigmentation) of the retinal pigment 
epithelium (RPE) (Figure 1). Drusen are multiple, usually 
discrete, round, slightly elevated, variable-sized, sub-RPE 
deposits in the macula and elsewhere in the fundus of both 
eyes. They can be seen as yellow or white spots in the 
fundus. The overlying RPE shows thinning, whereas the RPE 
between drusen shows thickening (Bressler and Rosbergerm 
1999; Gass et al 2003). In its earliest stages, AMD can be 
difﬁ  cult to diagnose. The dry form can advance and cause 
vision loss without turning into the wet form. It is possible 
to experience both forms at the same time, in one or both 
eyes. The onset and progression of either type does not follow 
any particular pattern. Sometimes the dry form progresses 
so slowly that a patient may not notice a change in vision. 
However, it can also suddenly turn into the wet form, even 
during early stage AMD. There is presently no way to tell if 
or when the dry form will turn into the wet form. Those with 
dry AMD have a 4%–12% chance per year of developing 
choroidal neovascularization (CNV). Patients with extremely 
large drusen (more than 500 microns in size) have an ever 
higher (30%) chance that their AMD will convert to the wet 
form within 5 years. Pigment clumping within the RPE may 
also be a risk factor for the wet form. All patients start with 
the dry form of macular degeneration. Atrophy of the RPE 
becomes more extensive with time. The end stage of the dry 
form involves the whole macula becoming affected as the 
geographic atrophy evolves.
In the wet type of AMD, new blood vessels grow and 
leak blood and ﬂ  uid under the macula. This can lead to 
retinal detachment, scarring, and irreversible vision loss. 
Blood vessels grow in from the choriocapillaris under the 
retina (CNV). The vessels grow through Bruch’s membrane 
and spread under or above the retinal pigment epithelium or 
both. These new blood vessels are very fragile, and easily 
leak and bleed. No blood vessels grow under the macula at 
ﬁ  rst. Instead, they start off to the side of the retina, and grow 
towards the center. For some, it can take only days to grow 
under the macula, for others it could take weeks. Abnormal 
blood vessels can reoccur, sometimes many years later. The 
consequences of abnormal vessel growth are hemorrhage 
and scar formation (disciform scarring). Although AMD 
tends to occur in one eye at a time, approximately 50% of International Journal of Nanomedicine 2007:2(1) 67
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Biomarkers
Inﬂ  ammation has been implicated in diseases of aging like 
Alzheimer’s disease, stroke, and cardiovascular disease. 
Several chronic systemic infections can result in subretinal 
neovascularization in younger individuals and could play 
a role in AMD. Therefore, attempts have been made to 
identify biomarkers for AMD. Carboxyethylpyrrole (CEP) 
is a biomarker that has been found recently to be associated 
with susceptibility to AMD. CEP protein adducts are free 
radical-induced oxidative protein modiﬁ  cations generated 
from docosahexaenoate (DHA)-containing lipids. DHA is 
easily oxidizable and abundant in ocular tissues where it is 
exposed to high photooxidative stress. Immunocytochemistry 
localized CEP to photoreceptor rod outer segments and retinal 
pigment epithelium in mouse retina. In a recent report, the 
mean level of CEP adducts was 1.5 fold higher (p = 0.004) and 
that of antibody titers in plasma was 2.3-fold higher (p = 0.02) 
in patients with AMD compared with normal age-matched 
controls (Gu et al 2003). Of individuals (n = 13) exhibiting 
both antigen and autoantibody levels above the mean for 
non-AMD controls, 92% had AMD. Based on the results, 
CEP immunoreactivity and autoantibody titer may have 
diagnostic utility in predicting AMD susceptibility. In the 
future, serum mass spectrometric proteomic pattern analysis 
will be used to identify additional AMD biomarkers. Being 
a complex disease, it is possible that multiple biomarkers 
will be needed to identify those at risk for AMD. The use 
of signature ion clusters may provide better accuracy and 
reliability in the process.
C-reactive protein (CRP) is produced by the liver and, 
similar to CEP, can be detected in blood serum by using an 
immunological test. It is present during episodes of acute 
systemic inﬂ  ammation, and higher levels of CRP have been 
associated with higher risk of developing cardiovascular 
disease. Since many factors associated with AMD are also 
related to cardiovascular disease, the relationship between CRP 
levels and AMD was examined in a study of 930 individuals 
from the multi-center Age-Related Eye Disease Study 
(AREDS) (Cho et al 2004). After adjustment for age, sex, and 
other variables, including smoking and body mass index, CRP 
levels were found to be signiﬁ  cantly higher among individuals 
with intermediate and advanced stages of AMD as compared 
to controls. A two-fold increased risk of AMD was associated 
with the highest levels of CRP for both smokers and non-
smokers. These results suggest that inﬂ  ammation may play a 
role in the pathophysiology of AMD and therefore anti-
inﬂ  ammatory agents might be useful for delaying the disease.
Figure 1 Fundus photographs showing the macula and optic nerve. A. Normal 
subject; B. Patient with multiple drusen within the posterior pole; C. Patient with 
advanced AMD showing geographic atrophy GA within the macula.
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patients who have wet AMD in one eye will also develop this 
condition in their second eye within 5 years. The progression 
of the disease varies from a few months to 3 years. Untreated, 
the majority of eyes affected with wet AMD will become 
functionally blind within approximately 2 years.International Journal of Nanomedicine 2007:2(1) 68
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General concepts in the 
pathogenesis of AMD
AMD is a multifactorial disease with characteristics that include 
drusen, hyperpigmentation, and/or hypopigmentation of the 
RPE, geographic atrophy and, in a subset of patients, late-stage 
CNV. To account for these characteristics, the major approaches 
to understanding the pathogenesis of AMD involve lipofuscin 
build-up in the RPE; oxidative stress; inﬂ  ammatory components; 
abnormal extracellular matrix; atrophy, apoptosis, and CNV.
Lipofuscin
During aging, many postmitotic cells accumulate autoﬂ  uorescent 
lysosomal storage bodies known as lipofuscin. Lipofuscin 
is the generic name given to a heterogeneous group of 
lipid/protein aggregates that have characteristic yellowish-
blue-green fluorescence emission when excited with 
ultraviolet light. These lipophilic inclusions are located 
within lysosomes and accumulate with age in a variety of 
postmitotic metabolically active cells throughout the body 
and constitute non-degradable end products. In most cell 
types the primary origin of this material is from the autophagy 
(degradation of intracellular organelles) of exhausted or 
damaged organelles (eg, mitochondria, Golgi, endoplasmic 
reticulum). However, for some cell types lipofuscin can be 
derived from the incomplete degradation of extracellular 
material taken into the cell by phagocytosis as in RPE cells 
(Mullen and LaVail 1976). Lipofuscin is often considered 
a marker for senescence and referred to as “age-pigment.” 
Oxidative modiﬁ  cation of cellular components through lipid 
peroxidation is thought to play a role in the mechanism of 
lipofuscin formation (Kennedy et al 1995). For example, 
lipid hydroperoxides and cyclic peroxides degrade to form 
aldehydes such as malondialdehyde and 4-hydroxynonenal 
that are precursors of fluorescent products. Lipofuscin 
accumulation has been correlated with a variety of non-ocular 
diseases, including ceroid-lipofuscinosis, cardiac hypertrophy, 
cirrhosis of the liver as well as with ocular diseases such as 
AMD, Best’s disease, and Stargardt disease (Boulton et al 
1984; Holz et al 1999; Mata et al 2000). Although lipofuscin 
has been studied for over a century and remains a focus of 
much research in AMD, there is still no deﬁ  nitive evidence 
that the accumulation of lipofuscin results in the impairment 
of cell function. The main difﬁ  culty in assessing the effects 
of lipofuscin accumulation on cell function is that the same 
factors that inﬂ  uence lipofuscin accumulation may have 
effects on cell function independent of their effects on the 
rate at which lipofuscin builds up in cells (Katz 2002).
RPE lipofuscin is unique in that its formation is 
dependent, in large part, on the ingestion of photoreceptor 
outer segments that provide a unique group of proteins, 
high concentrations of DHA-lipids, and retinoids. Notably, 
lipofuscin granules have also been observed in human 
photoreceptors, particularly cones (Iwasaki and Inomata 
1988). Formation of RPE lipofuscin appears to be closely 
associated with retinoids and a normally functioning visual 
cycle for the regeneration of visual pigments. For example, 
RPE65 knockout mice do not regenerate 11-cis-retinal 
and also do not accumulate signiﬁ  cant amounts of RPE 
lipofuscin (Katz and Redmond 2001). Animals deprived of 
dietary retinol exhibit very little age-related accumulation of 
lipofuscin in the RPE (Robison et al 1980). There are at least 
10 ﬂ  uorophores in the chloroform fraction of RPE lipofuscin 
(Eldred and Katz 1988). Two of these ﬂ  uorophores have now 
been identiﬁ  ed, namely, retinyl palmitate and A2E (Eldred 
and Laskey 1993; Ben-Shabat et al 2001). Carotenoids may 
also contribute to RPE lipofuscin since they are present in 
signiﬁ  cant amounts in macular photoreceptors and appear to 
contribute to lipofuscin formation in brain and heart.
Much has been learned recently about the relationship 
between lipofuscin and photoreceptor death by studying 
animal models of Stargardt disease. Stargardt disease is an 
inherited form of macular degeneration. The disease causing 
gene (ABCA4) encodes a photoreceptor membrane transport 
protein (rim protein) (Allikmets et al 1997; Weng et al 
1999). Patients show a substantial acceleration in lipofuscin 
accumulation in the RPE and because this pigment contains 
A2E, it has been proposed that rim protein is involved in 
transporting a compound formed in the ﬁ  rst step in synthesis 
of A2E (Weng et al 1999; Molday et al 2000). This is a 
reaction product of vitamin A aldehyde with ethanolamine, 
probably derived from phosphatidyl ethanolamine head 
groups of the photoreceptor outer segment membranes. 
One molecule of vitamin A aldehyde can react with the 
ethanolamine group of a phospholipid. It is proposed that 
transport proteins are involved in moving this intermediate 
across the outer segment membrane where presumably it is 
hydrolyzed and the retinal released is reduced to retinol which 
is delivered back to the RPE (Weng et al 1999). A defect in 
rim protein may interfere with this transport process resulting 
in retinal and phosphatidylethanolamine buildup in the outer 
segments. This allows a second molecule of vitamin A to 
react, and results in A2E in the shed disks and eventually to 
accelerated formation of lipofuscin ﬂ  uorophores in the RPE. 
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controversial. Following the initial report indicating a much 
higher incidence of certain alleles of that gene in familial 
macular degeneration (Allikmets et al 1997), a subsequent 
report in a different population showed comparable numbers 
of polymorphisms in AMD and normal subjects (Stone 
et al 1998).
Although a cause-and-effect relationship between 
RPE lipofuscin accumulation and altered cell function has 
not been established, there is a clear correlation between 
RPE lipofuscin content, impaired RPE cell function, and 
photoreceptor cell damage and loss. In particular, the 
accumulation of extracellular material on the basal side 
of the RPE has been associated with the development of 
AMD (Sarks et al 1999; Spraul et al 1999; Delori et al 
2000). Experimental manipulations that cause an increase 
in RPE lipofuscin accumulation have been shown to result 
in photoreceptor cell losses. For example, animals fed diets 
lacking certain antioxidant nutrients demonstrate a greatly 
accelerated rate of RPE lipofuscin-like pigment accumulation 
(Hayes 1974; Katz et al 1978). Accompanying the build-up 
of autoﬂ  uorescent storage bodies in the RPE are signiﬁ  cant 
decreases in photoreceptor cell densities. Thus, if lipofuscin 
accumulation interferes with normal RPE cell functions, 
the build-up of this pigment during aging is likely to play a 
major role in the development of AMD. Indeed, monitoring 
the fundus by scanning laser ophthalmoscopy has shown that 
zones of RPE exhibiting intense autoﬂ  uorescence are prone 
to atrophy (Scholl et al 2004).
Oxidative stress
Strong indirect evidence that oxidative damage plays a role in 
AMD comes from studies showing that smoking signiﬁ  cantly 
increases the risk of AMD (Seddon et al 1996) and that 
antioxidant vitamins and zinc can slow the progression of 
the disease for select individuals (Age-related eye disease 
study group 2001). Recent proteomic characterization of 
drusen established a direct molecular link between oxidative 
damage and AMD. Oxidative protein modiﬁ  cations uniquely 
generated from docosahexaenoate (DHA)-containing lipids, 
namely carboxyethylpyrrole (CEP) adducts, are more abundant 
in AMD than in normal Bruch’s’s membrane/RPE/choroid 
tissues. In addition, CEP adducts and CEP autoantibodies 
were found to be elevated in the plasma of AMD donors 
(Crabb et al 2002). The photo-oxidative environment in the 
retina and the lipid- and retinoid-rich photoreceptor outer 
segments provide an excellent source of reactive oxygen 
species and oxidation products. Accordingly, it has been 
proposed that oxidative protein modiﬁ  cations serve as the 
primary catalysts for macular degeneration associated with 
age. It has been further hypothesized that lipofuscin plays a 
major role in generating oxidative protein modiﬁ  cations and 
in the pathogenesis of AMD. For greater detail, the readers 
are referred to recent reviews of the role of oxidative stress 
in AMD (Beatty et al 2000; Liang and Godley 2003).
Inﬂ  ammatory components
There has been considerable attention recently to the 
inﬂ  ammation hypothesis due to the recent discovery of a 
polymorphism in the gene for complement factor H that 
occurs more frequently in AMD patients than in controls 
(Edwards et al 2005; Hageman et al 2005; Haines et al 
2005; Klein et al 2005). Anatomical studies provided 
initial evidence for the role of inflammation in CNV 
formation in AMD (Penfold et al 1987; Green and Enger 
1993). Subsequently, molecular evidence for the role of 
inﬂ  ammation in AMD pathogenesis has been developed 
and summarized (Hageman et al 2001; Johnson et al 2001; 
Anderson et al 2002). Protein components of drusen include 
immunoglobulin and components of the complement pathway 
associated with immune complex deposition (eg, C5b-9 
complex), molecules involved in the acute-phase response to 
inﬂ  ammation (eg, amyloid P component and 1-antitrypsin), 
proteins that modulate the immune response (eg, vitronectin, 
clusterin, apolipoprotein E, membrane cofactor protein, and 
complement receptor 1), major histocompatibility complex 
class II antigens, and HLA-DR and cluster differentiation 
antigens. Cellular components of drusen include RPE blebs, 
lipofuscin, and melanin, as well as choroidal dendritic cells. 
It has been suggested that choroidal dendritic cells are 
activated and recruited by injured RPE (eg, via monocyte 
chemotactic protein) and oxidized proteins and lipids in the 
Bruch’s membrane (Hageman et al 2001). A similar process 
occurs in atherosclerosis. The RPE cells respond to control 
dendritic cell activation by secreting proteins that modulate 
the immune response, including vitronectin, apolipoprotein 
E, and membrane cofactor protein. Cytoplasmic accumulation 
of vitronectin, apolipoprotein E, and other drusen-associated 
molecules suggests that the cells are subjected to a 
chronic sublethal complement attack (Johnson et al 2001). 
Complement attack can result in the elimination of surface-
associated membrane attack complexes (by shedding or 
endocytosis of cell membrane) and in the formation of 
extracellular deposits of immune complexes and complement 
intermediates. An increase in major histocompatibility International Journal of Nanomedicine 2007:2(1) 70
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complex class II immunoreactivity on retinal vascular 
elements and morphologic changes in microglia has been 
reported in eyes with incipient AMD (Penfold et al 1997). 
These immunological changes seemed to be related to early 
pathological changes in RPE pigmentation and drusen 
formation. Evidence of inﬂ  ammatory cell involvement in the 
later stages of AMD includes the presence of multinucleated 
giant cells and leukocytes in the choroid of AMD eyes 
(Dastgheib and Green 1994) and in excised CNVs (Seregard 
et al 1994). Macrophages and foreign body giant cells near 
Bruch’s membrane become more common when basal linear 
deposit is present (Killingsworth et al 1990). Activated 
macrophages and other inﬂ  ammatory cells secrete enzymes 
that can damage cells and degrade the Bruch’s membrane, 
and, by releasing cytokines, inﬂ  ammatory cells might foster 
CNV growth into the sub-RPE space. Thus, in AMD eyes, 
breaks in the Bruch’s membrane probably are the result and 
not the cause of CNVs. In some systems, degradation of the 
extracellular matrix (ECM) is associated with free radical 
release (Faury et al 1995).
Poorly degradable RPE debris and Bruch’s membrane 
components (eg, wide-spaced collagen) might stimulate 
chronic inﬂ  ammation (Burns and Feeney-Burns 1980; 
Loefﬂ  er and Lee 1992; van der Schaft et al 1993). Hageman 
and co-workers suggested that activation of choroidal 
dendritic cells might initiate an autoimmune response to 
retinal and/or RPE antigens or to neoantigens created within 
the Bruch’s membrane (Hageman et al 2001). Despite the 
RPE and retina being immune-privileged tissues , antiretinal 
and anti-RPE antibodies have been detected in the serum 
of patients with AMD (Penfold et al 1990; Hageman et al 
2001). Johnson and co-workers pointed out that complement 
activation and associated inﬂ  ammatory events occur in 
diseases exhibiting cellular degeneration and accumulation 
of abnormal tissue deposits, for example, atherosclerosis 
and Alzheimer’s disease (Johnson et al 2001). In these 
diseases, damaged cells and highly insoluble protein 
deposits and extracellular debris activate the classical and 
alternative complement pathways, resulting in chronic 
direct and bystander cellular damage with attendant cell 
surface blebbing, endocytosis, and upregulation of defense 
proteins.
Abnormal extracellular matrix (ECM)
The RPE deposits cytoplasmic material into the Bruch’s 
membrane throughout life, possibly to eliminate cytoplasmic 
debris or as a response to chronic inﬂ  ammation (Burns and 
Feeney-Burns 1980; Ishibashi et al 1986; Feeney-Burns 
et al 1990). Histologically, AMD eyes exhibit abnormal 
extracellular material in two locations: (1) between the 
RPE plasmalemma and the RPE basement membrane (basal 
laminar deposit), and (2) external to the RPE basement 
membrane within the collagenous layers of the Bruch’s 
membrane basal linear deposit (Green and Enger 1993). 
Although basal laminar deposit persists in areas of geographic 
atrophy, basal linear deposit disappears, which is consistent 
with the notion that basal linear deposit arises mostly from the 
RPE-photoreceptor complex (Sarks et al 1994). Basal linear 
deposit may be more speciﬁ  c to AMD than basal laminar 
deposit (Curcio and Millican 1999). Soft drusen can represent 
focal accentuations of basal linear deposit in the presence or 
absence of diffuse basal linear deposit–associated thickening 
of the inner aspects of the Bruch’s membrane. Soft drusen 
can also represent a localized accumulation of basal laminar 
deposit in an eye with diffuse basal laminar deposit. Thus, 
the abnormal ECM of AMD eyes includes basal laminar 
deposit, basal linear deposit, and their clinically evident 
manifestation, soft drusen.
Drusen represent the earliest clinical ﬁ  nding in AMD. 
Drusen composition and origin have been analyzed 
extensively. Small (ie, <63-μm-diameter) drusen generally 
do not signify the presence of AMD (Klein et al 1992; Green 
and Enger 1993; Sarks et al 1999). Excessive numbers of 
small hard drusen, however, can predispose to RPE atrophy 
at a relatively young age (Sarks et al 1999). Soft drusen are 
usually pale yellow and large (>63 μm in diameter), with 
poorly demarcated boundaries. Many different molecules have 
been identiﬁ  ed in drusen, including glycoconjugates containing 
mannose, sialic acid, N-acetylglucosamine, and β-galactose. 
Abnormal constituents of the ECM probably underlie 
the increased blue-green autoﬂ  uorescence of the Bruch’s 
membrane in AMD eyes (Marmorstein et al 2002).
A variety of drusen constituents (eg, vitronectin, 
apolipoproteins B and E, complement, and lipid) are present 
in atherosclerotic plaques, which may reﬂ  ect the association 
of some atherosclerosis risk factors with the development 
of AMD. Amyloid P component, C5, and 1-antitrypsin are 
acute-phase reactants (ie, upregulated expression in response 
to inﬂ  ammation), and vitronectin, C5, and apolipoprotein E 
have roles in mediating immune responses. These ﬁ  ndings 
have led to the suggestion that immune complex-mediated 
damage to RPE cells plays a role in the initiating events 
of drusen formation. It may be that terminal complement 
activation promotes drusen breakdown by enzymatic International Journal of Nanomedicine 2007:2(1) 71
Nanotech in AMD
digestion and phagocytosis (Johnson et al 2000). An immune 
response directed against RPE-derived antigens might be the 
trigger for drusen formation. In patients with AMD, delayed 
choroidal perfusion (as visualized with ﬂ  uorescein and 
indocyanine green angiography) and psychophysical retinal 
functional abnormalities may result from the diffusion barrier 
created by a thickened, lipid-laden Bruch’s membrane.
Atrophy, apoptosis, and CNV
The accumulation of extracellular debris alters Bruch’s 
membrane composition (ie, increased lipid and protein 
content) and permeability (eg, decreased permeability to 
water-soluble constituents in plasma, decreased amino acid 
transport, and possibly decreased bulk ﬂ  ow of extruded RPE-
derived cytoplasmic debris across the Bruch’s membrane). 
These changes may lead to impaired diffusion of waste 
products from and of hormones and nutrients to the RPE, 
including oxygen and vitamin A. In response to this metabolic 
distress, the RPE probably produces substances that stimulate 
CNV growth. Several investigators (Kvanta et al 1996; 
Lopez et al 1996; Frank 1997) have shown that RPE cells 
associated with CNVs produce VEGF and basic ﬁ  broblast 
growth factor, which may act synergistically to stimulate 
new blood vessel growth.
A decrease in visual acuity (VA) is often an early 
symptom of AMD and is the most commonly used outcome 
measure in clinical trials. As shown in Figure 2A, a functional 
fovea is required for normal (20/15–20/20) VA. In the normal 
macula, regions increasingly eccentric to the fovea have 
progressively lower resolution. Thus potential VA drops 
precipitously as geographic atrophy or CNV grows within the 
macula. An alternative potential outcome measure is shown 
in Figure 2B. The multifocal electroretinograms (mfERG) 
(Sutter and Tran 1992) elicit sub-microvolt electrical signals 
from focal regions within the posterior pole. With suitable 
scaling (Figure 2C), the complex topography of the macula 
can be visualized. MfERGs from patients with advanced 
geographic atrophy reﬂ  ect the extensive damage to cone 
photoreceptors within the macula (Figure 3).
Recent functional studies have also shown that the 
rod system is preferentially affected in aging and ARM. 
The topography of sensitivity loss at the posterior pole 
varies considerably among individual patients with 
AMD. However, in almost all patients (87%) who exhibit 
reduced light sensitivity, the magnitude of mean rod-
mediated sensitivity loss exceeds the magnitude of cone-
mediated sensitivity loss (Owsley et al 2000). In areas of 
increased fundus autoﬂ  uorescence in patients with AMD, 
rod-mediated sensitivity loss considerably exceeds cone-
mediated sensitivity loss (Scholl et al 2004). Preferential 
vulnerability of the rods in AMD has also been shown by 
histological studies. In eyes with late AMD virtually all 
surviving photoreceptors in the macula are cones, a reversal 
Figure 2 Functional test of the macula. A. Visual acuity tests the resolution limit 
of the retina. 20/20 vision requires an intact fovea. When the macula is damaged 
in AMD, the best acuity possible depends on the eccentricity of healthy retina. 
B. Multi-focal electroretinograms mfERGs can be obtained simultaneously from 
multiple locations within the macula. C. Three-dimensional false color representa-
tions are useful for visualizing the pattern of macula loss. The responses in B and C 
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of the normal predominance of rods (Curcio et al 1996, 
2000). In order to account for these ﬁ  ndings, Curcio and 
colleagues introduced the retinoid-deﬁ  ciency hypothesis 
for the pathogenesis of AMD (Curcio et al 2000; Curcio 
2001; Jackson et al 2002). According to this hypothesis, 
diffuse deposits of abnormal debris might account for both 
decreased choroidal perfusion and reduced rod sensitivity 
by acting as a diffusion barrier between the choroid and 
the RPE (Chen et al 1992). This interferes with the visual 
cycle, which includes transport of vitamin A derivatives 
such as 11-cis-retinal and all-trans-derivatives required by 
the photoreceptors. Lack of vitamin A affects primarily 
rods but eventually cones as well (Kemp et al 1989). 
Relative retinoid deﬁ  ciency caused by AMD could explain 
the topographic correspondence between rod-mediated 
sensitivity loss and RPE dysfunction as indexed by 
increased lipofuscin (Scholl et al 2004).
Implications for therapy
The basic characteristics outlined previously lead to ﬁ  ve 
general concepts regarding the cell biology of AMD (Zarbin 
2004). First, AMD involves aging changes plus additional 
pathological events. Second, in aging and AMD, oxidative 
stress causes RPE and, possibly, choriocapillaris injury. 
Third, in AMD (and perhaps in aging), RPE and, possibly, 
choriocapillaris injury results in a chronic inﬂ  ammatory 
response in Bruch’s membrane and the choroid. Fourth, RPE 
and, possibly, choriocapillaris injury and inﬂ  ammation lead 
to formation of an abnormal extra-cellular matrix (ECM). 
This abnormal ECM causes altered diffusion of nutrients 
to the retina and RPE, which may precipitate further RPE 
and retinal damage. Fifth, the abnormal ECM results in 
altered RPE choriocapillaris function, leading ultimately 
to atrophy of the retina, RPE, and choriocapillaris and/or 
to CNV growth. In this sequence of events, environment 
Figure 3 mfERGs in AMD. The responses above are from a patient with 20/100 VA. The bottom traces show a representative normal subject. For each patient, the left 
panels show individual responses, the center panels show summed responses from concentric rings of increasing eccentricity, and the right panels show three-dimensional 
representations.
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and genetics can alter any given patient’s susceptibility 
to the disease. Manipulation of environmental variables 
(eg, antioxidant levels) provides an opportunity for early 
therapeutic intervention. Gene and/or cellular therapy provide 
an opportunity for later, sight-restoring treatment.
Currently, most pharmacotherapies for AMD require 
periocular or intraocular administration. Although these 
approaches generally achieve improved therapeutic 
concentrations at the target tissues over systemically or 
topically applied drugs, the rapid clearance of these agents is 
still an issue. Repeated intraocular injection is not desirable 
due to the risk of surgery. Moreover, AMD, particularly 
CNV, probably require sustained release of drugs in order 
to achieve a successful outcome. To this end, continuous 
intraocular drug release has been developed through coupling 
desired drugs to liposomes, microparticles (1–1000 μm) or 
nanoparticles (1–1000 nm, generally 20–300 nm). These 
microscopic-size spheres are made from artiﬁ  cial or natural 
polymers. The commonly used polymers are polylactide 
(PLA), polylactide-co-glycolide (PLGA), and acrylic 
polymers, which can be degraded in vivo to form natural 
metabolites. The degradation rates can be regulated by 
changing their chemical composition and molecular weight 
to achieve long-term delivery ranging from months to years 
(Kranz et al 2000). Thus, this nanotechnology may offer 
several advantages for administration of drugs in vivo, such 
as controlled release, injectable and sterilizable formulation, 
and long shelf-life after lyophilization. In addition, drugs 
and genetic materials embedded or encapsulated into 
the NPs can be protected from immediate dilution and 
degradation and also overcome drug solubility issues. 
NPs can be synthesized to carry any number of molecules, 
including proteins, DNA, lipids and organic and inorganic 
substances (Prow et al 2006). Therefore the ﬂ  exibility of 
the target system of NPs is much greater than viral vectors. 
Some NPs can be made so small, such as dendrimer, less 
than 5 nm in diameter, which can easily enter the cells 
through tiny pores in cell membrane. For greater detail, 
the readers are referred excellent reviews of nanoparticles 
(PintoMartin et al 1996; Moghimi et al 2005; Moshfeghi 
and Peyman 2005).
While the majority of studies concerning biological 
application of nanotechnology have been focused primarily 
on delivery of chemotherapeutic agents for treating cancers 
in vivo, using NPs has also recently emerged as a promising 
tool for ocular research. Among many ocular diseases, AMD 
may be particularly suitable for usage of this technology as 
a future treatment option. As described earlier in this article, 
CNV is a major pathological condition in wet AMD, and 
VEGF is known to play a major role in the development of 
CNV. Thus, inhibition of VEGF expression in the retina by 
various methods has become a central focus for the treatment of 
neovascular (wet) AMD. Pegaptanib, an anti-VEGF aptamer, 
can selectively bind with VEGF and inhibit both the growth 
of blood vessels and vascular leakage, and was approved 
by the Food and Drug Administration (FDA) as the therapy 
for the treatment of neovascular AMD in December 2004 
(Chakravarthy et al 2006; D’Amico et al 2006). Most recently, 
ranibizumab (Lucentis™), another VEGF inhibitor, has also 
been approved by the FDA for treatment of this disease (Heier 
et al 2006; Rosenfeld et al 2006). Although both drugs showed 
some efﬁ  cacy in slowing disease progress and improving 
vision, they require multiple intravitreal injections, which 
cause serious adverse reactions, such as endophthalmitis, 
retinal detachment, and iatrogenic traumatic cataract, 
iridocyclitis and injection-site reactions (Chapman and 
Beckey 2006; D’Amico et al 2006; Rosenfeld et al 2006; Singh 
and Sears 2006). To reduce these side-effects resulting from 
multiple intravitreal injections, NPs may be used to deliver 
these drugs for sustained release in a longer time period, 
which may reduce the frequency of intravitreal injection. In 
fact, NPs loaded with ganciclovir was administered into the 
vitreous and was found to prolong the presence of drugs in 
the eye without toxicity (Merodio et al 2002).
In addition to delivering chemical drugs, nanoparticle-
mediated gene delivery has also emerged as a promising 
tool for gene therapy strategies (Vijayanathan et al 2002; 
Panyam and Labhasetwar 2003). Compared with viral vector-
mediated gene transfer, NPs-mediated delivery of therapeutic 
genes may reduce concerns about immnunogenecity and 
reversion of the engineered virus to the wild type (Vasir et al 
2006), while in the meantime providing biodegradability 
and safe pharmaceutical processing. As the pathogenesis of 
AMD involves RPE and/or phototoreceptor cells, therapeutic 
genes may be delivered to these cells by NPs. Indeed, NPs 
were shown to be taken up by RPE cells both in vitro and 
in vivo (Aukunuru et al 2003; Bourges et al 2003; Bejjani 
et al 2005; Moshfeghi and Peyman 2005). Compared with 
other non-viral gene delivery systems, NPs yield higher 
transfection efﬁ  ciency and no cell toxicity (Bejjani et al 2005). 
Recent studies using NPs to deliver a marker gene encoding 
green ﬂ  uorescent protein (GFP) into the subretinal space 
or vitreous of adult mice showed signiﬁ  cant levels of GFP 
expression in photoreceptors and RPE cells (Liu et al 2006; International Journal of Nanomedicine 2007:2(1) 74
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Naash 2006). Transgene expression can be observed within 
2–4 days after injection and remain detectable for the 
following several weeks (Bourges et al 2003; Liu et al 2006; 
Naash 2006). Interestingly, nanoparticles, due to their small 
size, injected in the vitreous can migrate through the retinal 
layers and tend to accumulate in the RPE cells (Figure 4) 
(Bourges et al 2003; Bejjani et al 2005). The transretinal 
movement of NPs following intravitreal injection may 
greatly facilitate intraocular drug/vector delivery to RPE/
choroids since intravitreal injection is technically much 
easier than subretinal injection. In addition, NPs can be used 
to deliver other types of nucleic acid fragments, such as 
oligonucleotides and neurotrophic factors. VEGF antisense 
oligonucleotides encapsulated by NPs were successfully 
delivered to ARPE-19 cells and inhibit VEGF secretion and 
mRNA expression (Aukunuru et al 2003). bFGF-loaded 
NPs showed signiﬁ  cant protection against photoreceptor 
degeneration in RCS rats due to sustained release of bFGF 
following intravitreal injection (Sakai et al 2006). Hence, 
the intracellular delivery of molecules by NPs to RPE or 
photoreceptor cells may open a wide range of therapeutic 
avenues for AMD. Although intraocularly injected NPs 
seem to primarily target photoreceptor and RPE cells, other 
retinal cells, although fewer, were also transduced (Bourges 
et al 2003; Liu et al 2006; Naash 2006). To facilitate cell-
speciﬁ  c binding and transduction into RPE or receptors and 
reduce unwanted side-effects, cell adhesion molecules or 
antibody may be conjugated onto NPs. This approach has been 
successfully tested in other tissues/cells and holds promise 
as a selective drug delivery system for speciﬁ  c cell types 
(Fishbein et al 2000; Thomas et al 2004; Dinauer et al 2005; 
Gullberg et al 2006).
One of the commonly used treatments for wet AMD 
(choroidal neovascularization) is photodynamic therapy 
(PDT), which is based on the delivery of a photosensitizer 
to the CNV site via a liposomal formulation of verteporﬁ  n 
(Renno and Miller 2001). For effective PDT against 
AMD, the selective delivery of photosensitizer to the CNV 
lesions is necessary. Although low-density lipoproteins 
and antibodies against endothelial cell markers have 
been used as carrier molecules (Schmidt-Erfurth et al 
1994), photosensitizer also distributes to normal blood 
vessels as they also express such markers. To circumvent 
this side effect to the normal retinal/choroidal vessels, 
nanotechnology-based PDT has been recently tested in 
laser-induced CNV animal models. Use of a dendritic 
photosensitizer (dendrimer porphyrin encapsulated by a 
polymeric micelle) led to a highly selective accumulation 
of photosensitizer in the CNV lesions, and signiﬁ  cantly 
enhanced the efﬁ  cacy of PDT, as indicated by the lower 
power energy of light that was required to occlude the 
CNV (Ideta et al 2005). These data provide a novel 
paradigm for treatment of AMD through dendrimer-based 
nanomedicine.
Patients with advanced AMD suffer severe vision loss 
due to RPE and photoreceptor cell degeneration. One of 
the logical treatment approaches is to replace dead RPE 
cells with normal healthy RPE, ie, RPE transplantation. 
Although extensive studies have been conducted in 
Figure 4 Phase contrast and ﬂ  uorescent microscopy of rat retina sections after 
intravitreous injection of nanoparticles loaded with RNFP plasmid: 7 days A, B 
and 14 days C, D after the initial intravitreal injection of nanoparticles. Inserts 
demonstrate the localization of the red ﬂ  uorescence expression of RNFP within 
the RPE nuclei. E. Hematoxylin-eosin stained rat retina section. Arrows show nuclei. 
Bars represent 20 μm. Modiﬁ  ed from Bejjani et al (2005) with permission.International Journal of Nanomedicine 2007:2(1) 75
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animals, RPE transplantation in human has failed so far to 
provide effective treatments. In a recent study, magnetite 
nanoparticles were used to construct and deliver RPE cell 
sheets in vitro (Ito et al 2005). The magnetically labeled 
RPE cells were seeded into an ultra-low-attachment 
plate and a magnet was placed under the well. After a 24 
hours of culture the magnetically labeled RPE formed an 
approximately 15-layered cell sheet. When the magnet was 
removed, the sheets were detached from the bottom of the 
plate and then harvested and transferred to a tissue culture 
dish. Subsequently, the cell sheets were attached onto the 
dish, and the cells growing on the sheets were observed. 
This nanotechnology-based methodology may provide a 
new approach for RPE transplantation. Another treatment 
approach for late-stage AMD patients is to implant an 
artiﬁ  cial retina (Loewenstein et al 2004). Artiﬁ  cial retinas 
require electric power. Recently NEI has established the 
National Center for Design of Biomimetic Nanoconductors. 
The ﬁ  rst task for the center is to design a class of devices 
for generating electric power—nanobatteries—for a wide 
array of implantable devices, including artiﬁ  cial retinas. 
With the artiﬁ  cial retina and accompanying nanobattery, it 
may be possible to substantially improve vision in patients 
with certain types of macular degeneration.
Conclusion
The ﬁ  rst proven “early” treatment for AMD is oral therapy 
with antioxidant vitamins and minerals. Other approaches may 
also be effective. Lipofuscin accumulation in RPE cells can 
be reduced by treatment with lutein, zeaxanthin, lycopene, 
or  -tocopherol or reversed by centrophenoxine treatment. 
The role of chronic inﬂ  ammation in AMD pathogenesis 
has led to the consideration of anti-inﬂ  ammatory therapy 
as treatment for the early stages of the disease (Hageman 
et al 2001; Anderson et al 2002). NPs represent an excellent 
potential delivery approach. Clearly, better knowledge of 
AMD pathogenesis is facilitating the design of more effective 
therapy for earlier stages of the disease. Nanotechnology will 
increasingly be useful for delivery of therapeutics. Better 
knowledge of the biological changes underlying AMD will 
also foster the development of sight restoring treatments for 
the late stages of AMD.
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